150 related articles for article (PubMed ID: 35526835)
1. Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to Determine Human Epidermal Growth Factor Receptor 2 Low Status for Breast Cancer.
Xu K; Bayani J; Mallon E; Pond GR; Piper T; Hasenburg A; Markopoulos CJ; Dirix L; Seynaeve CM; van de Velde CJH; Rea DW; Bartlett JMS
J Mol Diagn; 2022 Jul; 24(7):775-783. PubMed ID: 35526835
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of a Dual (Immunohistochemistry and Fluorescence In Situ Hybridization) HER2/neu Testing Strategy on Invasive Breast Cancers.
Hariri N; Zare S; Murphy J; Fadare O
Appl Immunohistochem Mol Morphol; 2021 Jan; 29(1):42-48. PubMed ID: 32205742
[TBL] [Abstract][Full Text] [Related]
3. Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer.
Stocker A; Trojan A; Elfgen C; Hilbers ML; Moskovszky L; Varga Z
Breast Cancer Res Treat; 2020 Sep; 183(2):311-319. PubMed ID: 32638236
[TBL] [Abstract][Full Text] [Related]
4. Validation of the Xpert Breast Cancer STRAT 4 Assay on the GeneXpert instrument to Assess Hormone Receptor, Ki67, and HER2 Gene Expression Status in Breast Cancer Tissue Samples.
Sewanywa L; Hale M; Michelow P; Mayne E; Wiggill T
Appl Immunohistochem Mol Morphol; 2023 Oct; 31(9):613-620. PubMed ID: 37800656
[TBL] [Abstract][Full Text] [Related]
5. RT-qPCR is helpful to distinguish the clinicopathological features of HER2 immunohistochemistry 0 and 1.
Yue M; Wu S; Wang X; Cai L; Wang X; Yang H; Liu Y
Pathol Res Pract; 2023 Jul; 247():154532. PubMed ID: 37267721
[TBL] [Abstract][Full Text] [Related]
6. Discordance Between Immunohistochemistry and In Situ Hybridization to Detect HER2 Overexpression/Gene Amplification in Breast Cancer in the Modern Age: A Single Institution Experience and Pooled Literature Review Study.
Memon R; Prieto Granada CN; Harada S; Winokur T; Reddy V; Kahn AG; Siegal GP; Wei S
Clin Breast Cancer; 2022 Jan; 22(1):e123-e133. PubMed ID: 34120846
[TBL] [Abstract][Full Text] [Related]
7. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
[TBL] [Abstract][Full Text] [Related]
8. Incidence, Clinicopathologic Features, HER2 Fluorescence In Situ Hybridization Profile, and Oncotype DX Results of Human Epidermal Growth Factor Receptor 2-Low Breast Cancers: Experience From a Single Academic Center.
Hu Y; Jones D; Zhao W; Tozbikian G; Wesolowski R; Parwani AV; Li Z
Mod Pathol; 2023 Jul; 36(7):100164. PubMed ID: 36967073
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Partial Weak Staining in Normal Breast Epithelium on the Reliability of Immunohistochemistry Results in HercepTest-positive Breast Cancer.
Farra C; Fedda F; Tfayli A; Tawil A; Zaatari G; Ashkar H; Issa G; Boulos F
Clin Breast Cancer; 2019 Oct; 19(5):340-344. PubMed ID: 31213407
[TBL] [Abstract][Full Text] [Related]
10. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
[TBL] [Abstract][Full Text] [Related]
11. Identification of HER2 Immunohistochemistry-Negative, FISH-Amplified Breast Cancers and Their Response to Anti-HER2 Neoadjuvant Chemotherapy.
Gibbons-Fideler IS; Nitta H; Murillo A; Tozbikian G; Banks P; Parwani AV; Li Z
Am J Clin Pathol; 2019 Jan; 151(2):176-184. PubMed ID: 30339245
[TBL] [Abstract][Full Text] [Related]
12. Correlation of In Situ HER2 RNA Expression With HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Categories in Breast Cancer.
Tseng YF; Li YC; Lee YH; Hu HW; Zhang MS; Hung TC; Lien HC
Arch Pathol Lab Med; 2024 Mar; 148(3):e48-e56. PubMed ID: 37639453
[TBL] [Abstract][Full Text] [Related]
13. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
Loi S; Dafni U; Karlis D; Polydoropoulou V; Young BM; Willis S; Long B; de Azambuja E; Sotiriou C; Viale G; Rüschoff J; Piccart MJ; Dowsett M; Michiels S; Leyland-Jones B
JAMA Oncol; 2016 Aug; 2(8):1040-7. PubMed ID: 27100299
[TBL] [Abstract][Full Text] [Related]
14. Comparison of immunohistochemistry with fluorescence in situ hybridization in determining the human epidermal growth factor receptor 2 status of breast cancer specimens: a multicenter study of 3,149 Chinese patients.
Han X; Shi Y; Ma L; Lyu Z; Yang H; Yao J; Li J; Li B; Qin Y
Chin Med J (Engl); 2014; 127(2):246-53. PubMed ID: 24438611
[TBL] [Abstract][Full Text] [Related]
15. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.
Wolff AC; Somerfield MR; Dowsett M; Hammond MEH; Hayes DF; McShane LM; Saphner TJ; Spears PA; Allison KH
Arch Pathol Lab Med; 2023 Sep; 147(9):993-1000. PubMed ID: 37303228
[TBL] [Abstract][Full Text] [Related]
16. HER2-Low Breast Cancers.
Zhang H; Katerji H; Turner BM; Hicks DG
Am J Clin Pathol; 2022 Mar; 157(3):328-336. PubMed ID: 34519765
[TBL] [Abstract][Full Text] [Related]
17. Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization.
Solomon JP; Dell'Aquila M; Fadare O; Hasteh F
Am J Clin Pathol; 2017 Apr; 147(4):432-437. PubMed ID: 28340220
[TBL] [Abstract][Full Text] [Related]
18. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
[TBL] [Abstract][Full Text] [Related]
19. Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer.
Kaufman PA; Bloom KJ; Burris H; Gralow JR; Mayer M; Pegram M; Rugo HS; Swain SM; Yardley DA; Chau M; Lalla D; Yoo B; Brammer MG; Vogel CL
Cancer; 2014 Sep; 120(17):2657-64. PubMed ID: 24930388
[TBL] [Abstract][Full Text] [Related]
20. Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
Krystel-Whittemore M; Xu J; Brogi E; Ventura K; Patil S; Ross DS; Dang C; Robson M; Norton L; Morrow M; Wen HY
Breast Cancer Res Treat; 2019 Aug; 177(1):61-66. PubMed ID: 31144151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
